TY  - JOUR
AU  - Stahler, Arndt
AU  - Hoppe, Beeke
AU  - Na, Il-Kang
AU  - Keilholz, Luisa
AU  - Müller, Lothar
AU  - Karthaus, Meinolf
AU  - Fruehauf, Stefan
AU  - Graeven, Ullrich
AU  - Fischer von Weikersthal, Ludwig
AU  - Goekkurt, Eray
AU  - Kasper, Stefan
AU  - Kind, Andreas Jay
AU  - Kurreck, Annika
AU  - Alig, Annabel Helga Sophie
AU  - Held, Swantje
AU  - Reinacher-Schick, Anke
AU  - Heinemann, Volker
AU  - Horst, David
AU  - Jarosch, Armin
AU  - Stintzing, Sebastian
AU  - Trarbach, Tanja
AU  - Modest, Dominik Paul
TI  - Consensus Molecular Subtypes as Biomarkers of Fluorouracil and Folinic Acid Maintenance Therapy With or Without Panitumumab in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa, AIO KRK 0212).
JO  - Journal of clinical oncology
VL  - 41
IS  - 16
SN  - 0732-183X
CY  - Alexandria, Va.
PB  - American Society of Clinical Oncology
M1  - DKFZ-2023-00706
SP  - 2975-2987
PY  - 2023
N1  - 2023 Jun 1;41(16):2975-2987
AB  - Consensus molecular subtypes (CMSs) were evaluated as prognostic and predictive biomarkers of patients with RAS wild-type metastatic colorectal cancer (mCRC) receiving fluorouracil and folinic acid (FU/FA) with or without panitumumab (Pmab) after Pmab + mFOLFOX6 induction within the randomized phase II PanaMa trial.CMSs were determined in the safety set (ie, patients that received induction) and full analysis set (FAS; ie, randomly assigned patients who received maintenance) and correlated with median progression-free survival (PFS) and overall survival (OS) since the start of induction or maintenance treatment and objective response rates (ORRs). Hazard ratios (HRs) and 95
LB  - PUB:(DE-HGF)16
C6  - pmid:37018649
DO  - DOI:10.1200/JCO.22.02582
UR  - https://inrepo02.dkfz.de/record/275259
ER  -